{"entity":{"id":"nct05644561","kind":"trial","name":"Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis","aka":[],"tldr":"A phase 3 trial of Ravulizumab in childhood cancers, run by Alexion Pharmaceuticals, Inc., active and no longer recruiting.","summary":"Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis is a phase 3 interventional study registered as NCT05644561 by Alexion Pharmaceuticals, Inc., with 12 participants enrolled, started 2023-06-24 and due to reach its primary completion in 2026-07-15. Interventions recorded: Ravulizumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05644561","url":"https://clinicaltrials.gov/study/NCT05644561"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":["ravulizumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05644561","phase":"3","setting":"Phase 3, Open-label, Single-arm, Multicenter Study Evaluating Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants (6 to <18 Years) With Generalized Myasthenia Gravis (gMG)","sponsor":"Alexion Pharmaceuticals, Inc.","enrolled":12,"outcomes":[]},"route":"/trials/nct05644561/","neighbours":{"cancer":[{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/"}],"drug":[{"id":"ravulizumab","kind":"drug","name":"Ravulizumab","route":"/drugs/ravulizumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}